SK287330B6 - Použitie Src proteínu alebo nukleovej kyseliny obsahujúcej nukleotidovú sekvenciu kódujúcu Src proteín na prípravu farmaceutickej kompozície na moduláciu angiogenézy - Google Patents

Použitie Src proteínu alebo nukleovej kyseliny obsahujúcej nukleotidovú sekvenciu kódujúcu Src proteín na prípravu farmaceutickej kompozície na moduláciu angiogenézy Download PDF

Info

Publication number
SK287330B6
SK287330B6 SK1811-2000A SK18112000A SK287330B6 SK 287330 B6 SK287330 B6 SK 287330B6 SK 18112000 A SK18112000 A SK 18112000A SK 287330 B6 SK287330 B6 SK 287330B6
Authority
SK
Slovakia
Prior art keywords
src
angiogenesis
protein
src protein
tissue
Prior art date
Application number
SK1811-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK18112000A3 (sk
Inventor
David A. Cheresh
Brian Eliceiri
Pamela L. Schwartzberg
Original Assignee
The Scripps Research Institute
The Government Of The United States Of America National
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute, The Government Of The United States Of America National filed Critical The Scripps Research Institute
Publication of SK18112000A3 publication Critical patent/SK18112000A3/sk
Publication of SK287330B6 publication Critical patent/SK287330B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SK1811-2000A 1998-05-29 1999-05-28 Použitie Src proteínu alebo nukleovej kyseliny obsahujúcej nukleotidovú sekvenciu kódujúcu Src proteín na prípravu farmaceutickej kompozície na moduláciu angiogenézy SK287330B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8722098P 1998-05-29 1998-05-29
PCT/US1999/011780 WO1999061590A1 (en) 1998-05-29 1999-05-28 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src

Publications (2)

Publication Number Publication Date
SK18112000A3 SK18112000A3 (sk) 2001-09-11
SK287330B6 true SK287330B6 (sk) 2010-07-07

Family

ID=22203825

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1811-2000A SK287330B6 (sk) 1998-05-29 1999-05-28 Použitie Src proteínu alebo nukleovej kyseliny obsahujúcej nukleotidovú sekvenciu kódujúcu Src proteín na prípravu farmaceutickej kompozície na moduláciu angiogenézy

Country Status (24)

Country Link
US (1) US7585841B2 (es)
EP (1) EP1082415B1 (es)
JP (1) JP4806487B2 (es)
KR (1) KR20010085261A (es)
CN (1) CN1304567C (es)
AT (1) ATE506073T1 (es)
AU (1) AU762955C (es)
BR (1) BR9910787A (es)
CA (1) CA2330025C (es)
CZ (1) CZ302918B6 (es)
DE (1) DE69943374D1 (es)
DK (1) DK1082415T3 (es)
ES (1) ES2361659T3 (es)
HK (1) HK1041289A1 (es)
HU (1) HU227985B1 (es)
MX (1) MXPA00011821A (es)
NO (1) NO327610B1 (es)
PT (1) PT1082415E (es)
RU (1) RU2222342C2 (es)
SK (1) SK287330B6 (es)
TR (1) TR200100430T2 (es)
UA (1) UA75565C2 (es)
WO (1) WO1999061590A1 (es)
ZA (1) ZA200007321B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
DK1082415T3 (da) * 1998-05-29 2011-06-14 Scripps Research Inst Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1250155B1 (en) 1999-12-22 2008-04-16 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
US7485414B2 (en) * 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP2086528B1 (en) * 2006-10-31 2016-10-26 University Of Toledo Na+/k+-atpase-specific peptide inhibitors of src and src family kinases
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
CN102427728A (zh) 2009-03-13 2012-04-25 阿布拉科斯生物科学有限公司 用硫代秋水仙碱衍生物进行联合治疗
RU2539859C2 (ru) * 2013-05-06 2015-01-27 Государственное научное учреждение Всероссийский научно-исследовательский институт орошаемого овощеводства и бахчеводства Российской академии сельскохозяйственных наук (ГНУ ВНИИОБ РАСХН) Способ производства цукатов из кабачков различной степени спелости

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1998016638A1 (en) * 1995-10-13 1998-04-23 The Rockefeller University Consolidated ligands with increased affinities and methods of use thereof
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
DK1082415T3 (da) * 1998-05-29 2011-06-14 Scripps Research Inst Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity

Also Published As

Publication number Publication date
ES2361659T3 (es) 2011-06-21
HUP0102614A3 (en) 2005-11-28
PT1082415E (pt) 2011-07-04
HU227985B1 (en) 2012-07-30
NO20006026D0 (no) 2000-11-28
JP2002516344A (ja) 2002-06-04
JP4806487B2 (ja) 2011-11-02
ZA200007321B (en) 2002-03-08
AU4101399A (en) 1999-12-13
NO20006026L (no) 2001-01-24
US7585841B2 (en) 2009-09-08
CN1319131A (zh) 2001-10-24
HUP0102614A2 (hu) 2001-11-28
NO327610B1 (no) 2009-08-31
AU762955B2 (en) 2003-07-10
CA2330025C (en) 2009-03-17
HK1041289A1 (en) 2002-07-05
US20060009412A1 (en) 2006-01-12
WO1999061590A9 (en) 2000-03-09
KR20010085261A (ko) 2001-09-07
RU2222342C2 (ru) 2004-01-27
DK1082415T3 (da) 2011-06-14
MXPA00011821A (es) 2004-07-30
CA2330025A1 (en) 1999-12-02
DE69943374D1 (de) 2011-06-01
TR200100430T2 (tr) 2002-05-21
CN1304567C (zh) 2007-03-14
SK18112000A3 (sk) 2001-09-11
EP1082415A1 (en) 2001-03-14
UA75565C2 (uk) 2006-05-15
EP1082415A4 (en) 2003-07-09
EP1082415B1 (en) 2011-04-20
CZ302918B6 (cs) 2012-01-18
AU762955C (en) 2005-03-24
BR9910787A (pt) 2001-10-30
CZ20004435A3 (en) 2001-06-13
ATE506073T1 (de) 2011-05-15
WO1999061590A1 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
KR100813818B1 (ko) 혈관 형성 및 혈관 투과성 조절제 및 억제제
US6685938B1 (en) Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US7585841B2 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src
AU2020294264A1 (en) Treatment of retinitis pigmentosa using engineered meganucleases
JP2000502570A (ja) Ｆｈｉｔタンパク質および核酸ならびにそれに基づく方法
JPH09509324A (ja) 増殖阻止ホメオボックス遺伝子
KR100805098B1 (ko) 단백질 키나제 Ｒａｆ 또는 Ｒａｓ를 포함하는 혈관형성조절에 유용한 조성물 및 이를 포함하는 제품
Schenk et al. Gene therapy: future therapy for erectile dysfunction
WO2023033025A1 (ja) プラスミド導入剤、プラスミド導入用キット、医薬組成物及びプラスミド導入方法
BR102020015226A2 (pt) Proteína recombinante capaz de inibir a formação de novos vasos sanguíneos
MXPA02006207A (es) Angiogenesis y moduladores e inhibidores de la permeabilidad vascular

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20160528